Recursion Pharmaceuticals's total assets for Q3 2024 were $726.50M, a decrease of -6.36% from the previous quarter. RXRX total liabilities were $201.94M for the fiscal quarter, a 5.50% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.